HCW Biologics (HCWB) Total Non-Current Liabilities (2021 - 2025)

HCW Biologics (HCWB) has 5 years of Total Non-Current Liabilities data on file, last reported at $21.1 million in Q4 2025.

• Quarterly Total Non-Current Liabilities fell 43.08% year-over-year to $21.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $21.1 million (down 43.08% YoY) and the FY2025 annual result came in at $21.1 million, down 43.08% from the prior year.
• Total Non-Current Liabilities declined to $21.1 million in Q4 2025, from $26.9 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $37.0 million in Q4 2024 to a low of $1.1 million in Q2 2022.
• A 5-year average of $15.6 million and a median of $11.3 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2023 — Total Non-Current Liabilities jumped 852.13% — and 2025, when it sank 43.08%.
• Tracing HCWB's Total Non-Current Liabilities over 5 years: stood at $2.3 million in 2021, then soared by 303.45% to $9.4 million in 2022, then jumped by 59.97% to $15.0 million in 2023, then jumped by 146.98% to $37.0 million in 2024, then slumped by 43.08% to $21.1 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $21.1 million (Q4 2025), $26.9 million (Q3 2025), and $27.3 million (Q2 2025), per Business Quant data.